{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:21:55Z","timestamp":1790659315859,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K01 DK105108"],"award-info":[{"award-number":["K01 DK105108"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mid-Atlantic Nutrition Obesity Research Center"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30DK072488"],"award-info":[{"award-number":["P30DK072488"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jdiacomp.2016.08.018","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T01:41:09Z","timestamp":1472866869000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Greer","family":"Waldrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Goud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhramar","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0005","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1463-1326.2010.01334.x","article-title":"Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial","volume":"13","author":"Arechavaleta","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1463-1326.2009.01187.x","article-title":"Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes","volume":"12","author":"Aschner","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0020","unstructured":"AstraZeneca; Bristol-Myers Squibb 18-week add-on to metformin comparison of saxagliptin and sitagliptin in adult patients with type 2 diabetes (T2D). Clin [Internet]National Libr Med NCT00666458."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2011.77","article-title":"GLP-1 and energy balance: An integrated model of short-term and long-term control","volume":"7","author":"Barrera","year":"2011","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/03007990802597951","article-title":"Efficacy and safety of biphasic insulin aspart 70\/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea","volume":"25","author":"Bergenstal","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1463-1326.2007.00820.x","article-title":"Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes","volume":"10","author":"Bolli","year":"2008","journal-title":"Obesity and Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0045","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2011.01463.x","article-title":"Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study","volume":"13","author":"Bosi","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1479164111404574","article-title":"Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76weeks","volume":"8","author":"Chacra","year":"2011","journal-title":"Diabetes & Vascular Disease Research"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0070","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00125-013-2905-1","article-title":"Efficacy and safety over 26weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: A randomised clinical trial","volume":"56","author":"Charbonnel","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0075","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2337\/dc12-1333","article-title":"Once-weekly exenatide versus once- or twice-daily insulin detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas","volume":"36","author":"Davies","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jdiacomp.2012.11.008","article-title":"Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials","volume":"27","author":"Del Prato","year":"2013","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0085","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0090","first-page":"1","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial","volume":"6736","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0095","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs--FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0100","unstructured":"Eli Lilly and Company A study in participants with type 2 diabetes mellitus (AWARD-4). Clin [Internet]National Libr Med NCT01191268."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0105","unstructured":"Eli Lilly and Company A study in participants with type 2 diabetes mellitus (AWARD-2). Clin [Internet]National Libr Med NCT01075282."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0110","unstructured":"Eli Lilly and Company Effect of exenatide plus metformin vs. insulin aspart plus metformin on glycemic control and hypoglycemia in patients with type 2 diabetes. Clin [Internet]National Libr Med NCT00434954."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1464-5491.2010.02938.x","article-title":"A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study","volume":"27","author":"Filozof","year":"2010","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdiacomp.2012.09.007","article-title":"Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes","volume":"27","author":"Fonseca","year":"2013","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1463-1326.2011.01553.x","article-title":"Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage","volume":"14","author":"Fonseca","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0130","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","article-title":"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial","volume":"380","author":"Gallwitz","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diabres.2008.09.037","article-title":"Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea","volume":"83","author":"Gao","year":"2009","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0145","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1463-1326.2008.00859.x","article-title":"Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea","volume":"10","author":"Garber","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12119","article-title":"Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: Long-term (52-week) extension of a 52-week randomised controlled trial","author":"G\u00f6ke","year":"2013","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0165","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1463-1326.2011.01458.x","article-title":"Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin","volume":"13","author":"Graefe-Mody","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0170","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0175","first-page":"343","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0180","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone","volume":"94","author":"Hollander","year":"2009","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0185","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/dom.12414","article-title":"Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1year in people with type 2 diabetes currently taking","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0190","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.clinthera.2012.07.007","article-title":"Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug (s)","volume":"34","author":"Inagaki","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0195","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1463-1326.2009.01056.x","article-title":"Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial","volume":"11","author":"Jadzinsky","year":"2009","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0200","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0205","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0210","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0215","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0220","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2010.01233.x","article-title":"Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study","volume":"12","author":"Matthews","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0225","unstructured":"Merck Sharp Study of sitagliptin for the treatment of type 2 diabetes mellitus with inadequate glycemic control on insulin (MK-0431-260). Clin [Internet]National Libr Med NCT01462266."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0230","unstructured":"Merck Sharp & Dohme Corp MK0431A comparative study in patients with type 2 diabetes (0431A-079)(completed). In: Clin. [Internet].National Libr. Med. http:\/\/clinicaltrials.gov\/show\/NCT00482729."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0235","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/dom.12234","article-title":"A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea","volume":"16","author":"Moses","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0240","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0245","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/dom.12012","article-title":"Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study","volume":"15","author":"Nauck","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/dme.12003","article-title":"Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with Type2 diabetes: An open-label randomized trial","volume":"30","author":"Nauck","year":"2013","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0255","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","article-title":"Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicentre, randomised, double-blind, placebo-controlled study","volume":"63","author":"Nauck","year":"2009","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0260","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0265","unstructured":"Novo Nordisk The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes. Clin [Internet]National Libr Med NCT01617434."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0270","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/dom.12115","article-title":"Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents","volume":"15","author":"Philis-Tsimikas","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0275","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/dom.12121","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)","volume":"15","author":"Pinget","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0280","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0290","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1463-1326.2011.01390.x","article-title":"The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus","volume":"13","author":"Reasner","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0295","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/dom.12382","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 1): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled, trial in patients with type 2 diabetes mellitus not controlled on pioglitazone \u00b1 metfo","volume":"16","author":"Reusch","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0300","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0305","first-page":"1","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4)","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0310","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0315","unstructured":"Sanofi Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA). Clin [Internet]National Libr Med NCT01147250."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0320","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination withmetformin in adult patients with type 2 diabetes mellitus","volume":"26","author":"Scheen","year":"2010","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0325","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2008.00850.x","article-title":"Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia*","volume":"10","author":"Scherbaum","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0330","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0335","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0340","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1742-1241.2010.02353.x","article-title":"Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study","volume":"64","author":"Seck","year":"2010","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0345","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0350","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2337\/dc09-1488","article-title":"Costs and consequences associated with newer medications for glycemic control in type 2 diabetes","volume":"33","author":"Sinha","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0355","unstructured":"Takeda Efficacy and safety of alogliptin plus metformin in patients with type 2 diabetes. Clin [Internet]National Libr Med NCT01023581."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0360","unstructured":"Takeda Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in patients with type 2 diabetes mellitus. Clin [Internet]National Libr Med NCT00856284."},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0370","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0375","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0380","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jamainternmed.2014.2894","article-title":"Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus","volume":"174","author":"Vijan","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0385","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0390","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsb\u00f8ll","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0395","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1463-1326.2011.01530.x","article-title":"Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes J","volume":"14","author":"Wainstein","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0400","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacc.2015.12.058","article-title":"Incretin-based therapy for diabetes: What a cardiologist needs to know","volume":"67","author":"Waldrop","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0405","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","article-title":"HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea","volume":"57","author":"Weissman","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0410","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0415","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diabres.2011.07.035","article-title":"Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial","volume":"94","author":"Yang","year":"2011","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0425","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-1241.2010.02589.x","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of \u03b2-cell function in patients with type 2 diabetes","volume":"65","author":"Yoon","year":"2011","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0430","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","article-title":"DPP4 in cardiometabolic disease: Recent insights from the laboratory and clinical trials of DPP4 inhibition","volume":"116","author":"Zhong","year":"2015","journal-title":"Circulation Research"},{"key":"10.1016\/j.jdiacomp.2016.08.018_bb0435","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716304457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716304457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:09:07Z","timestamp":1761005347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716304457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1056872716304457"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.08.018","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}